Siren, L.L.C. Phathom Pharmaceuticals, Inc. Transaction History
Siren, L.L.C.
- $2.26 Trillion
- Q4 2024
A detailed history of Siren, L.L.C. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Siren, L.L.C. holds 460,753 shares of PHAT stock, worth $2.8 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
460,753
Previous 460,753
-0.0%
Holding current value
$2.8 Million
Previous $8.33 Billion
55.09%
% of portfolio
0.17%
Previous 0.42%
Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
158Shares Held
68.6MCall Options Held
52.3KPut Options Held
635K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$61.5 Million4.92% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$45.4 Million13.31% of portfolio
-
Jennison Associates LLC7.06MShares$42.9 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA3.67MShares$22.3 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$21.3 Million28.4% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $238M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...